Geriatric Psychopharmacology Research Group

About the Geriatric Psychopharmacology Research Group

Our research looks at neuropsychiatric symptoms associated with illness, which include apathy, agitation and cognitive changes. These are common consequences of many brain disorders, such as mild cognitive impairment, vascular mild cognitive impairment, CADASIL, Alzheimer’s disease and vascular dementia.

Our lab focuses on:

the underlying neurobiology of neuropsychiatric symptoms
precision interventions
using novel drugs or repurposing existing drugs for new indications
identifying and managing modifiable risk factors to prevent cognitive decline.

Projects

Interested in participating in a study? Contact memoryresearch@sunnybrook.ca

Active Studies

View all Clinical Trials

CAnnabidioL Medication Intervention Trial (CALM-IT) This study will look at how cannabidiol (CBD) can help control symptoms of agitation in persons living with Alzheimer’s disease (AD).
Nabilone for Agitation Blinded Intervention Trial (NAB-IT) This study will look at nabilone as a treatment for agitation in persons with Alzheimer’s disease (AD).
rTMS Apathy Clinical Trial (REACT) This pilot study will investigate rTMS as a treatment for apathy in AD in individuals receiving methylphenidate and individuals not receiving medication for apathy.